PT  - JOURNAL ARTICLE
AU  - Maes, Mailis
AU  - Higginson, Ellen
AU  - Pereira-Dias, Joana
AU  - Curran, Martin
AU  - Parmar, Surendra
AU  - Khokhar, Fahad
AU  - Cuchet-Lourenço, Delphine
AU  - Lux, Janine
AU  - Sharma-Hajela, Sapna
AU  - Ravenhill, Benjamin
AU  - Mahroof, Razeen
AU  - Solderholm, Amelia
AU  - Forrest, Sally
AU  - Sridhar, Sushmita
AU  - Brown, Nicholas
AU  - Baker, Stephen
AU  - Navapurkar, Vilas
AU  - Dougan, Gordon
AU  - Scott, Josefin Bartholdson
AU  - Conway Morris, Andrew
TI  - Secondary pneumonia in critically ill ventilated patients with COVID-19
AID  - 10.1101/2020.06.26.20139873
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.26.20139873
4099  - http://medrxiv.org/content/early/2020/06/28/2020.06.26.20139873.1.short
4100  - http://medrxiv.org/content/early/2020/06/28/2020.06.26.20139873.1.full
AB  - Background Pandemic COVID-19 caused by the coronavirus SARS-CoV-2 has a high incidence of patients with severe acute respiratory syndrome (SARS). Many of these patients require admission to an intensive care unit (ICU) for invasive artificial ventilation and are at significant risk of developing a secondary, ventilator-associated pneumonia (VAP).Objectives To study the incidence of VAP, as well as differences in secondary infections, and bacterial lung microbiome composition of ventilated COVID-19 and non-COVID-19 patients.Methods In this prospective observational study, we compared the incidence of VAP and secondary infections using a combination of a TaqMan multi-pathogen array and microbial culture. In addition, we determined the lung microbime composition using 16S RNA analyisis. The study involved eighteen COVID-19 and seven non-COVID-19 patients receiving invasive ventilation in three ICUs located in a single University teaching hospital between April 13th 2020 and May 7th 2020.Results We observed a higher percentage of confirmed VAP in COVID-19 patients. However, there was no statistical difference in the detected organisms or pulmonary microbiome when compared to non-COVID-19 patients.Conclusion COVID-19 makes people more susceptible to developing VAP, partly but not entirely due to the increased duration of ventilation. The pulmonary dysbiosis caused by COVID-19, and the array of secondary infections observed are similar to that seen in critically ill patients ventilated for other reasons.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe use of discard samples surplus to that required for clinical testing, and anonymised data review were conducted under the consent waiver granted by Leeds West NHS Research Ethics Committee (ref: 20/YH/0152). Not registered as observational study of routine clinical practice.Funding StatementThis study was funded by the National Institute for Health Research [Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust]. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Dr Conway Morris is supported by a Clinical Research Career Development Fellowship from the Wellcome Trust (WT 2055214/Z/16/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The TaqMan multi-pathogen array has been adopted as a routine clinical service in our institution following a previous evaluation study. The use of discard samples surplus to that required for clinical testing, and anonymised data review were conducted under the consent waiver granted by Leeds West NHS Research Ethics Committee (ref: 20/YH/0152).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw sequencing data is available in SRA under project number PRJNA642012 https://www.ncbi.nlm.nih.gov/bioproject/PRJNA642012